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INTRODUCTION
Recent clinical trials have shown that the addition of trastu-
zumab and lapatinib to standard chemotherapy improves the 
disease-free survival of ERBB2 (HER2)-overexpressing (HER2+) 
breast cancer in adjuvant settings, as well as in metastatic can-
cer [1-3]. The clinical benefits of targeted anti-HER2 therapy 
are confined to patients with HER2+ breast cancer. Thus, valid 
determination of HER2 status is a prerequisite for establishing 
adequate treatment strategies for breast cancer patients, regard-
less of disease stage [4].
Immunohistochemistry (IHC) is not completely accurate in 
determining HER2 status, especially in equivocal cases; how-
ever, it has become a widely accepted method for HER2 deter-
mination because of its practical convenience. IHC results are 
often hampered by various methodological heterogeneities, 
such as inadequate storage of tissue samples, variation in the 
fixation procedure, different antibodies, lack of formal training 
and education, and inter-observer variation despite its techno-
logical convenience [5,6].  
DNA is biologically more stable than protein; thus, it is less 
likely to be affected by preservation conditions. Fluorescence 
in situ hybridization (FISH) allows the direct quantification of 
gene copy numbers on an individual slide and results can be 
more objective than IHC. 
FISH has been regarded as the gold standard for HER2 status 
determination in breast cancer. However, FISH has not been 
as widely accepted as IHC in clinics because it is more time-
intensive and requires special equipment, such as a fluorescence 
microscope and multicolor filters. Chromogenic in situ hybrid-
ization (CISH) has been introduced to overcome the practical 
limitations of FISH. CISH uses a simple IHC-like peroxidase 
reaction and, unlike FISH, does not require additional equip-
ment [7,8]. Moreover, most pathologists are familiar with per-
oxidase-based immunostaining. Another advantage of CISH 
over FISH in routine practice is that simultaneous verification 
of histology can be performed using CISH. With FISH, adequate 
histopathological evaluation of individual cells is impossible. 
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Purpose: Valid determination of HER2 status is a prerequisite to 
establish an adequate treatment strategy for breast cancer pa-
tients, regardless of the disease stage. The goal of this study was 
to examine the feasibility of the newly developed silver-enhanced 
in situ hybridization (SISH) technique as an alternative to fluores-
cence in situ hybridization (FISH) for HER2 assay in primary inva-
sive breast cancer. Methods: FISH and SISH for HER2 amplifica-
tion were performed using tissue microarray. Both methods were 
used in 257 consecutive primary breast cancers. Results: HER2 
amplification was observed in 62 (23.1%) of a total of 257 breast 
cancers based on SISH. Of the 257 breast cancers measured 
using both methods, the results of the two methods were con-
sistent in 248 (concordance, 96.5%; kappa=0.903). When we 
compared HER2 amplification in the primary tumor with the meta-
static lymph nodes of the same patients, HER2 amplification was 
observed in nine cases (14.0%) out of 64 cases in which HER2 
was not amplified in the primary tumors. In contrast, HER2 status 
was completely preserved in metastatic lymph nodes showing 
HER2 amplification in the primary tumor. Conclusion: These results 
indicate that SISH can be a feasible alternative to FISH in the clinical 
setting. In node-positive breast cancer, confirmation of the HER2 
status of the metastatic lymph nodes appears to be mandatory, 
regardless of the HER2 status of the primary tumors.
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The recent development of dual-color probes for HER2 and 
CEP17 enables the identification of polysomy using CISH [9]. 
Silver-enhanced in situ hybridization (SISH) has been devel-
oped as an alternative method to FISH and CISH for HER2 
determination [10-12]. SISH is a novel bright-field in situ hybrid-
ization technique similar to CISH. It is a fully automated sys-
tem developed by Ventana Medical System (Tucson, USA), that 
improves the efficiency and consistency of bright-field in situ 
hybridization, reducing the risk of error. Automated detection 
of chromogenic signals also allows HER2 and CEP17 assays to 
be performed on consecutive tissue slides.
We performed this study to examine the feasibility of SISH 
as an alternative to FISH for assaying HER2 amplification in 
clinical breast cancer. Specifically, we compared the results 
from SISH with those from FISH. Additionally, we analyzed the 
HER2 status in primary breast cancer with metastatic cancer 
of the lymph nodes in the same patients.
METHODS
Case selection
In total, 257 primary invasive breast carcinomas were collected 
at Inje University Sanggye Paik Hospital, Seoul, Korea. Histo-
pathological classification and determination of the tumor col-
lecting regions were performed using hematoxyline and eosin 
(H&E) slides. Invasive ductal carcinomas were graded as 1, 2, 
or 3 using the Nottingham histological grading system [13],   
in ascending degree of malignancy. This study was conducted 
under the approval of the Institutional Review Board of Inje 
University Sanggye Paik Hospital.
Tissue microarray block
Recipient blocks were made with purified agar in 3.8×2.2 cm 
frames. Holes (2 mm) were made on the recipient blocks using 
a core needle and the agar core was discarded. Donor blocks 
were prepared after thorough evaluation of the H&E slides. 
Three case cores were obtained separately from each primary 
breast cancer sample and metastatic lymph node specimen. 
Representative cancer portions taken from matching donor 
blocks were transplanted to the recipient blocks using a 2-mm 
core needle. Recipient blocks were framed in a mold that is 
used to frame conventional paraffin blocks, and paraffin was 
then added to the frame. Consecutive 4.0-μm thick sections 
were cut from the recipient blocks using an adhesive-coated 
slide system (Instrumedics Inc., Hackensack, USA) supporting 
the cohesion of the 2-mm array elements on the glass [8]. 
Immunohistochemistry
For HER2 IHC, the FDA-approved HercepTest
TM (DAKO, 
Carpinteria, USA) was used manually according to the manu-
facturer’s protocol. Prior to staining, tissue slides were depar-
affinized and rehydrated. For epitope retrieval, the slides were 
soaked in a heated water bath at 95-99°C for 40 minutes. A per-
oxidase-blocking reagent (100 μL) was applied for 5 minutes. 
Then, 100 μL of anti-HER2 protein reagent was added and the 
slides were incubated for 30 minutes. A visualization reagent 
(100 μL) was applied for 30 minutes. A substrate-chromogen 
solution (diaminobenzidine) was then added and the color was 
developed for 10 minutes. The slides were counterstained by 
immersion in a bath of hematoxylin for 2-5 minutes.
IHC staining was semiquantitatively evaluated using the 
American Society of Clinical Oncology/College of American 
Pathologists (ASCO/CAP) guidelines. Staining results were 
scored as 0 (negative; no staining), 1 (negative; faint/barely per-
ceptible incomplete membrane staining), 2 (equivocal; weak to 
moderate complete membrane staining in >10% of the tumor 
cells or strong, complete membrane staining in <30% of the 
tumor cells), and 3 (positive; strong complete membrane stain-
ing in >30% of the tumor cells) [4]. Positive and negative con-
trols were used to validate each assay run.
Chromogenic in situ hybridization
Prior to in situ hybridization, tissue slides were deparaffinized 
and incubated in a SPOT-Light Heat Pretreatment buffer (Zymed 
Inc., South San Francisco, USA) at 92-100°C for 15 minutes. 
After washing with phosphate buffer saline (PBS), 100 mL of 
SPOT-Light Tissue Pretreatment Enzyme (Zymed) was applied 
at 37°C for 5 minutes. The slides were washed with PBS and 
dehydrated with graded concentrations of ethanol. A coverslip 
was placed on the slide after application of 15 μL of digoxigenin-
labeled HER2/neu probe. The slides were placed on a 95°C hot 
plate for 5-10 minutes and were then incubated at 37°C for 16-
24 hours. After incubation, the slides were treated with 0.5× 
sodium chloride citrate for 5 minutes and then washed with 
PBS/Tween solution. The slides were treated with 3% hydro-
gen peroxide for 10 minutes and 100 μL of FITC-sheep anti-
digoxigenin (Zymed) was then applied for 30-60 minutes. After 
washing with PBS, 100 μL of HRP-goat anti-FITC (Zymed) was 
applied for 30-60 minutes. After washing again with PBS, 150 μL 
of 3,3-diaminobenzidine tetrahydrochloride was applied for 
20-30 minutes. The slides were counterstained with H&E after 
washing with purified water and dehydrated with ethanol and 
xylene. Amplification of HER2 was defined when the gene copy 
number was more than four or when a large copy cluster was 
seen in more than 50% of cancer cell nuclei.
Silver-enhanced in situ hybridization
HER2 SISH was performed on an automated instrument, a 278   Kyeongmee Park, et al.
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Ventana Benchmark (Ventana Medical Systems), according   
to the manufacturer’s protocols for INFORM HER2 DNA and 
chromosome 17 probes. Testing for the HER2 gene and chro-
mosome 17 was performed on sequential sections. Two sections 
were baked at 60°C for 20 minutes. The HER2 DNA probe 
was denatured at 95°C for 12 minutes and hybridization was 
performed at 52°C for 2 hours. The chromosome 17 probe was 
denatured at 95°C for 12 minutes and hybridization was per-
formed at 44°C for 2 hours. After hybridization, appropriate 
stringency washes were performed three times at 72°C for the 
HER2 probe and three times at 59°C for the chromosome 17 
probe. Both DNP-labeled probes were visualized using a rabbit 
anti-DNP primary antibody and the ultraView SISH Detection 
Kit (Ventana). The slides were counterstained with hematoxylin 
for examination by light microscopy.
Evaluation of HER2 gene amplification status was performed 
in a blind manner using the ASCO/CAP guidelines [4]. HER2/ 
CEP 17 SISH signals were selected and 20 nonoverlapping nuclei 
were analyzed. The ratio of HER2/CEP 17 was then calculated. 
A ratio of <1.8 indicated that HER2 gene was not amplified, 
whereas a ratio of >2.2 indicated amplification of the gene. The 
equivocal range was defined as HER2/CEP 17 ratios from 1.8 
to 2.2. For the equivocal cases, signals from 20 further tumor 
nuclei were counted in a second target area and a new ratio was 
calculated. Benign breast epithelial cells and other adjacent 
benign cells were used as internal controls.
Fluorescence in situ hybridization
Consecutive sections (4 μm) were cut from the paraffine 
blocks. Before hybridization, the sections were deparaffinized, 
air dried, and dehydrated in 100% ethanol after incubation at 
56°C for 24 hours. The slides were treated with a wash buffer 
(Abbott Laboratories, Abbott Park, USA) for 3 minutes after 
treatment with 0.2 N HCl for 20 minutes. A pretreatment solu-
tion (Abbott) was applied for 30 minutes at 80°C and the slides 
were then washed with purified water. The slides were serially 
treated twice with a wash buffer at 45-50°C and air dried. The 
slides were fixed in 10% buffered formalin for 10 minutes and 
then washed with wash buffer at 45-50°C. For denaturation, 
the slides were immersed in a denaturation solution (Abbott) 
for 5 minutes at 72°C followed by serial dehydration with 70%, 
85%, and 100% ethanol at 45-50°C. For hybridization, a 10 μL 
LSI HER-2/CEP17 probe (PathVysion
TM; Abbott) was applied 
and a coverslip was placed over the probe. After overnight   
hybridization at 37°C in a humidified chamber, the slides were 
washed at 72°C with a post-hybridization wash buffer (Abbott) 
for 2 minutes. Nuclei were counterstained with 10 μL 4,6-       
diamino-2-phenylindole (Abbott). Centromere 17 (CEP) and 
HER2 copy numbers were estimated for the predominant tumor 
cell populations. 
Following the ASCO/CAP guidelines, at least 20 malignant 
nonoverlapping nuclei were selected from two different areas 
in each patient, and the HER2/CEP 17 ratio was calculated [4]. 
Amplification was scored as negative (ratio <1.8) or positive 
(ratio >2.2) for gene amplification. The equivocal range was 
defined as HER2/CEP 17 ratios from 1.8 to 2.2. For the equiv-
ocal cases, signals from 20 further tumor nuclei were counted 
in a second target area and a new ratio was calculated. Benign 
breast epithelial cells and other adjacent benign cells were used 
as the internal control.
Data analysis
Results from CISH, SISH, and FISH were merged and ana-
lyzed. A chi-squared test was used for data analysis. Correlations 
between the results were estimated using Spearman’s correla-
tion coefficients (kappa). A kappa value of 1 denotes complete 
agreement, values more than 0.75 denote excellent agreement, 
values between 0.4 and 0.75 denote fairly good agreement, and 
values less than 0.4 denote poor agreement. Statistical analyses 
were performed using SPSS version 15.0 (SPSS Inc., Chicago, 
USA). Statistical significance was defined as a p-value of less 
than 0.05.
RESULTS
HER2 amplification measured by SISH was observed in 62 
cases (24.1%) of the 257 studied breast cancers (Figures 1, 2). 
In contrast, the frequency of HER2 amplification was 64 cases 
by CISH (24.9%) and 61 cases (23.7%) by FISH. The median 
patient age was 46 (range, 31-82) years. The estrogen receptor 
(ER) was expressed in 160 patients (62.3%). Lymph node metas-
tasis was present in 143 patients (55.6%). When we analyzed 
Figure 1. Silver-enhanced in situ hybridization revealed two HER2 black 
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the HER2 status according to the clinical and pathological char-
acteristics of the patients, HER2 amplification was significantly 
increased in both high grade (p<0.05) and ER-negative tumors 
(p<0.05).
We compared the results from SISH with those from CISH 
and FISH. Results of SISH and FISH were consistent in 248 of 
the 257 tumors. The concordance between the two methods 
was 96.5% (kappa=0.903). Results from SISH and CISH were 
consistent in 247 tumors, with a concordance rate of 96.2%. 
HER2 amplification was detected by CISH in 6 cases, although 
the amplification signals were not observed by SISH in these 
cases. Of these 6 cases, polysomy was observed in 3 (50.0%) 
(Table 1). 
HER2 protein expression was analyzed using a HercepTest
TM 
and we compared these results with HER2 amplification status, 
measured by SISH, CISH, and FISH (Table 2). In 43 cases with 
HercepTest 3+ results, HER2 amplification was confirmed in 
42 cases (97.7%). Of the 189 tumors with HercepTest 0-1+   
results, HER2 amplification was observed in 6 (3.1%) by FISH, 
3 (1.6%) by SISH and 7 (3.7%) by CISH. In contrast, HER2 
amplification was confirmed in 52-68% by FISH, SISH, and 
CISH (Table 2).
We compared HER2 amplification in the primary tumor with 
metastatic lymph nodes of the same patients. Eighty-seven out 
of the 143 cases were available to evaluate the HER2 gene status 
in metastatic lymph nodes. Of the 87 cases, HER2 amplification 
was observed in 9 cases (14.0%) in which HER2 was not am-
plified in the main tumors. In contrast, HER2 status was com-
pletely preserved in metastatic lymph nodes in which HER2 
was amplified in the primary tumor (Table 3).
DISCUSSION
We used the INFORM HER2 SISH technology developed 
by Ventana Medical Systems (Tucson, USA) in the current 
study. SISH was more rapidly performed than FISH, taking 
only 6 hours. When we analyze DNA amplification using FISH, 
overnight hybridization is usually required. Furthermore, SISH 
requires only a conventional light microscope, making its use 
possible for routine pathology laboratories.
The current study indicates that the results obtained with 
SISH for HER2 amplification were consistent with those of 
Table 2. Comparison of HercepTest™ with the results of in situ hybrid-
izations
HercepTest™ score
0-1 2 3 Total
HER2 amplification by FISH
   Absent 183 (93.4) 12 (6.1) 1 (0.5) 196
   Present   6 (9.8)   13 (21.3) 42 (68.9)   61
HER2 amplification by SISH
   No amplification 186 (95.4)   8 (4.1) 1 (0.5) 195
   Amplification   3 (4.9)   17 (27.4) 42 (67.7)   62
HER2 amplification by CISH
   No amplification 182 (94.3) 10 (5.2) 1 (0.5) 193
   Amplification     7 (10.9)   15 (23.4) 42 (65.7)   64
Values are presented as number of cases (%).
FISH=fluorescence in situ hybridization; SISH=silver-enhanced in situ hybrid-
ization; CISH=chromogenic in situ hybridization.
Table 3. Relationship of HER2 status between main tumor and corre-
sponding metastatic lymph node HER2 amplification of main tumors
Lymph node SISH
No  
amplification
Amplification Total
Primary tumor SISH
   No amplification 55   9 64
   Amplification 0 23 23
SISH=silver-enhanced in situ hybridization.
Table 1. Correlation between SISH and FISH/CISH for HER2 assay
HER2 amplification by SISH
Absent Present Total p-value
HER2 amplification FISH                 Concordance 96.5% <0.001
   Absent 191 (97.5) 5 (2.5) 196
   Present   4 (6.5) 57 (93.5)   61
HER2 amplification by CISH                 Concordance 96.2% <0.001
   Absent 189 (97.9) 4 (2.1) 193
   Present     6 (9.4)* 58 (90.6)   64
Values are presented as number of cases (%).
SISH=silver-enhanced in situ hybridization; FISH=fluorescence in situ hybrid-
ization; CISH=chromogenic in situ hybridization.
*3 cases: polysomy.
Figure 2. Silver-enhanced in situ hybridization showed increased HER2 
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FISH, showing a high concordance, of 96.5%. According to the 
ASCO/CAP guidelines, more than 95% concordance should 
be achieved to validate novel ISH technology or IHC proce-
dures [4]. Results of the current study are comparable with the 
accuracy of other studies using SISH for HER2 assay [14,15]. 
The two studies that compared SISH with FISH reported a 
concordance rate of 94-98%.
The overall frequency of HER2 amplification ranges between 
12% and 20% for primary breast cancers [16,17]. Identification 
of proper candidates for anti-HER2 treatment is the most     
important step to maximize treatment efficacy while mini-
mizing unnecessary costs due to improper patient selection. 
Some patients who will not benefit from anti-HER2 treatment 
may be exposed to unnecessary treatment due to inaccurate 
identification. In contrast, some patients may lose the oppor-
tunity to receive more effective and less toxic target therapy. 
However, uncertainty remains regarding the best approach for 
selecting patients for HER2 treatment. There is also uncertainty 
regarding the most appropriate and efficient testing strategy 
and the reliability and interpretation of the HER2 test results.
While FISH is the gold standard for the HER2 assay, it is not 
always available, even in developed countries. The main obsta-
cles to the wide acceptance of FISH are high costs and labor-
intensiveness due to the requirement of specialized instruments 
and the typical lack of quality control systems in medium- or 
small-volume institutions. However, FISH is currently per-
formed in centralized and qualified centers, even in large mul-
ticenter clinical trials [18-20]. Nevertheless access to FISH test-
ing and reluctance to export tissue samples are other barriers 
to centralized FISH testing. For this reason, IHC remains the 
most popular HER2 assaying method, despite its inferiority to 
FISH.
Based on the current study along with another report, SISH 
could be a reasonable alternative to FISH for HER2 status deter-
mination because of its practical convenience for clinical breast 
cancer testing. Education for standardization and quality con-
trol is significantly less complicated for SISH than for FISH 
because of its technical simplicity. Moreover SISH has an advan-
tage in that stained samples can be stored at room temperature 
and do not readily decay over time.
Another type of bright-field in situ hybridization for HER2 
is CISH. We previously reported CISH results for HER2 am-
plification with 188 consecutive breast cancers, which were 
compared with results obtained by FISH using the same tissue 
microarray [8]. Concordance between CISH and FISH was 
94% in that report, which is comparable to the results of the 
current study showing concordance between SISH and FISH. 
In the current study, we performed CISH with the same tissue 
array blocks. CISH results were almost identical to those ob-
tained by FISH and SISH. SISH and CISH may be practical 
alternatives to FISH in situations in which FISH is not available 
for the HER2 assay. However, the previous single-color CISH 
determined the HER2 gene and we could not identify polysomy. 
CISH is not yet considered an alternative choice in the selec-
tion of patients to be treated with trastuzumab.
Discordance of HER2 amplification between primary breast 
cancer and metastatic lesions, including axillary lymph nodes, 
has been extensively investigated. In the current study, we iden-
tified 9 discordant cases out of 87 matched samples. Although 
most data suggest good overall concordance between primary 
and metastatic lesions [21,22], some data have demonstrated 
discordance in up to 20% of cases [23]. Whether HER2 status is 
maintained in distant metastatic lesions remains controversial. 
A recent study reported that a positive conversion of HER2 
status was observed in a significant proportion of metastatic 
lesions [24]. In that study, HER2 status was discordant between 
primary tumors and metastatic sites in 127 of a total of 382 
cases. The investigators reported that positive conversion of 
HER2 was observed in 37 cases. However, HER2 status was 
only measured by immunohistochemistry in that study, thus 
the validity of the study was hampered by 2+ cases. In the cur-
rent study, HER2 status was not accurate by immunohistochem-
istry in 2+ cases. Furthermore in the current study, HER2 am-
plification was observed in 52-68% of HercepTest 2+ cases by 
FISH, SISH, and CISH.
The wide range of variation in HER2 conversion between 
primary tumor and metastatic lesions stems from the different 
time intervals and metastatic sites among studies. Our results 
suggest that a positive conversion of HER2 status in synchro-
nous metastatic lymph nodes is not rare. We previously reported 
that HER2 status between primary tumors and corresponding 
lymph nodes were concordant in 93% of cases [25]. In that study, 
we used immunohistochemistry alone for HER2 assay in the 
lymph nodes. A concordance of 90% is similar to that observed 
in the current study. However, HER2 was not overexpressed 
in the metastatic lymph node, while the primary tumor showed 
HER2 overexpression and amplification in 5 cases. This result 
somewhat differs from that of the current study.
We hypothesize that discordance of HER2 amplification 
between primary tumors and metastatic sites could increase 
with increasing time intervals due to the de novo conversion of 
HER2 status. Clonal outgrowth with genetic modification might 
influence the discordant HER2 status in metastatic sites with 
increasing time intervals and adjuvant systemic therapy. This 
might contribute to the relatively lower frequency of discor-
dance observed in our study. The high concordance of HER2 
status between invasive and intraductal components of individ-
ual tumors from our previous study [25] may shed light on the Silver-Enhanced In Situ Hybridization Is Feasible for Assaying HER2  281
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relatively low incidence of positive HER2 status conversion in 
the current study. In 270 consecutive breast cancers, HER2 
amplification was consistent between the invasive and intra-
ductal components of 266 individual tumors in our previous 
study [25].
Assay methods might influence the lower frequency of dis-
cordance, because most studies used IHC for HER2 assay [21, 
22,24]. At this point, we cannot conclude whether de novo 
conversion of HER2 amplification occurs in a synchronous or 
metachronous pattern.
SISH showed accuracy comparable with that of FISH with 
respect to HER2 status determination in formalin-fixed paraf-
fin-embedded tissues. SISH may be a viable alternative to FISH 
due to its practical convenience in a clinical situation where 
FISH is not available. HER2 amplification in metastatic axillary 
lymph nodes coincided well with that of primary tumors. How-
ever, discordance between primary tumors and metastatic axil-
lary lymph nodes was observed in a considerable proportion 
of studied breast cancers. In this situation, negative conversion 
of HER2 amplification was rare whereas positive conversion 
in axillary lymph nodes was common.
In node-positive breast cancers, as well as in recurrent or met-
astatic settings, HER2 status confirmation in metastatic nodes, 
regardless of HER2 status in primary tumors, appears to be 
necessary for proper management. This can provide the oppor-
tunity for less toxic anti-HER2 biologic treatments to a signifi-
cant proportion of breast cancer patients who otherwise are not 
candidates for anti-HER2 biologic treatment. Thus, the results 
of this study will contribute to improved clinical outcomes in 
breast cancer.
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